Men's health in type 2 diabetes. Focus on metabolic and antioxidant properties of testosterone

Oxidative stress is the pathogenetic basis for the progression of T2DM. It is important to evaluate antioxidant properties of testosterone medications used for the management of male hypogonadism (a comorbidity of T2DM). Aim: to evaluate antioxidant properties of testosterone hormone replacement therapy (THRT) in patients with type 2 diabetes. Material and methods: the randomized (1:1) clinical trial included 108 patients with type 2 diabetes, visceral obesity and hypogonadism. The treatment group received THRT for 12 months. The changes in metabolic (glycemic and non-glycemic) parameters and activity of antioxidant protection enzymes - superoxide dismutase (SOD) and glutathione peroxiase, (GPO), were evaluated. The ΔOxS index was suggested to characterize the changes in oxidative stress. Results: THRT was associated with improved metabolic and antioxidant status. Increased SOD and GPO activity against a background of THRT was 32.4 ± 5.6 U/l and 580 ± 68 U/ml, respectively (p < 0.05). ΔOxS was characterized by positive changes only in the treatment group, indicating a decrease in oxidative stress during THRT. Conclusions: in patients with visceral obesity and T2DM, THRT contributed to improvement in metabolic parameters and elimination of oxidative stress and glucose-lypo-toxicity, and that could potentially reduce the risk of progression of type 2 diabetes and its complications.

сахарный диабет 2-го типа, окислительный стресс, супероксиддисмутаза, глутатионпероксидаза, тестостерон, мужское здоровье, type 2 diabetes, oxidative stress, superoxide dismutase, glutathione peroxidase, testosterone, men's health

1. Аметов А.С., Камынина ЛЛ., Ахмедова З.Г Глюкозо- и липотоксичность - взаимоотягощающие факторы при сочетании сахарного диабета типа 2 и ожирения. Врач, 2014, 4: 21-23.

2. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol., 2013, 169(6): 725-33.

3. Nieschlag E, Behre HM, Nieschlag S. Andrology. Male reproductive health and dysfunction. Internistische Praxis, 2011, 51(4): 751.

4. Пашкова Е.Ю., Рождественская О.А. Возрастной андрогенный дефицит у мужчин: этиология, клиника, диагностика, лечение. Андрология и генитальная хирургия, 2015, 1: 95-101.

5. Гусакова Д.А., Ефремов Е.А., Мельник Я.И., Симаков В.В. Роль окислительного стресса в патофизиологическом механизме эректильной дисфункции. Consilium Medicum, 2013, 15(7): 28-31.

6. Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat Rev Endocrinol, 2013, 9(8): 479-93.

7. De Maddalena C, Vodo S, Petroni A, Aloisi AM. Impact of testosterone on body fat composition. J Cell Physiol, 2012, 227(12): 3744-8.

8. Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. J Endocrinol, 2014 Jan 27, 220(3): R37-55.

9. Araki E, Nishikawa T. Oxidative stress: A cause and therapeutic target of diabetic complications. J Diabetes Investig, 2010, 1(3): 90-6.

10. Aprioku JS. Pharmacology of free radicals and the impact of reactive oxygen species on the testis. J Reprod Infertil, 2013, 14(4): 158-72.

11. Yang J, Zong X, Wu G, Lin S, Feng Y, Hu J. Taurine increases testicular function in aged rats by inhibiting oxidative stress and apoptosis. Amino Acids, 2015 Aug, 47(8): 1549-58.

12. Higuchi M, Celino FT, Shimizu-Yamaguchi S, Miura C, Miura T. Taurine plays an important role in the protection of spermatogonia from oxida-tive stress. Amino Acids, 2012, 43(6): 2359-69.

13. Fatani AJ, Al-Rejaie SS, Abuohashish HM, Al-Assaf A, Parmar MY, Ahmed MM. Lutein dietary supplementation attenuates streptozo-tocin-induced testicular damage and oxidative stress in diabetic rats. BMC Complement Altern Med, 2015. 15: 204.

14. Tsang CK, Liu Y, Thomas J, Zhang Y, Zheng XF. Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat Commun, 2014 Mar 19, 5: 3446.

15. Zhang L, Wu S, Ruan Y, Hong L, Xing X, Lai W. Testosterone suppresses oxidative stress via androgen receptor-independent pathway in murine cardiomyocytes. Mol Med Rep, 2011, 4(6): 1183-8.

16. Тишова Ю.А., Калинченко С.Ю. Роль коррекции гипогонадизма в лечении метаболического синдрома у мужчин и аспекты безопасности терапии препаратом тестостерона пролонгированного действия (результаты двойного слепого рандомизированного плацебо-контролируемого исследования). Ожирение и метаболизм, 2010, 26: 36-43.

17. Ametov AS, Kamynina L.L., Akhmedova Z.G. Glucose- and lipo-toxicity - mutual confounding factors in type 2 diabetes mellitus combined with obesity. Vrach, 2014, 4: 21-23.

18. Pashkova E.Y., Rozhdestvenskaya O.A. Age-dependent androgen deficiency in men: etiology, clinical pattern, diagnosis and treatment. Andrologiya i Genitalnaya Khirurgiya, 2015, 1: 95-101.

19. Gusakova D.A., Efremov E.A., Melnik Y.I., Simakov V.V. The role of oxidative stress in the pathophysiological mechanisms of erectile dysfunction. Consilium Medicum, 2013, 15(7): 28-31.

20. Tishova Y.A., Kalinchenko S.Y. The role of managing hypogonadism in the treatment of metabolic syndrome in men and safety aspects of long-acting testosterone therapy (results of a randomized, double-blind, placebo-controlled study). Ozhirenie i Metabolizm, 2010, 26: 36-43.